Management of Molluscum Contagiosum
For uncomplicated molluscum contagiosum, watchful waiting with spontaneous resolution in 6-12 months is acceptable, but active treatment with 10% potassium hydroxide or cryotherapy is preferred when lesions are cosmetically bothersome, in patients with underlying eczema, or to prevent transmission and reduce psychosocial burden. 1
Clinical Context and Natural History
Molluscum contagiosum is a benign viral skin infection presenting as skin-colored papules with central umbilication, affecting 5-11% of children aged 0-16 years, most commonly on the trunk, face, and extremities 1. While mostly asymptomatic, lesions may present with pain, itching, redness, or bacterial superinfection 1.
Key timeline: Uncomplicated lesions typically resolve spontaneously in 6-12 months, though complete resolution can take up to 4 years 1.
Treatment Algorithm
First-Line Options (Similar Efficacy)
10% Potassium Hydroxide:
- Clearance rate: 73.8% 2
- Minimal local side effects
- Well-tolerated in children
- Preferred for multiple lesions or sensitive areas
Cryotherapy with Liquid Nitrogen:
- Similar efficacy to potassium hydroxide in children 1
- Important caveat: Risk of postinflammatory hyperpigmentation or, uncommonly, scarring 1
- May be more frightening to children 3
Curettage:
- Highest clearance rate: 97.8% 2
- Immediate removal but requires procedural tolerance
- Risk of scarring and discomfort
FDA-Approved Therapies (Recent Evidence)
Berdazimer gel 10.3%:
- Achieves >50% lesion clearance within 6 weeks to 3 months 4
- Favorable safety profile, particularly for pediatric patients 2
- Patient-acceptable clearance rates
Cantharidin 0.7%:
- FDA-approved with meaningful clearance rates 4
- Conflicting evidence: Open-label studies show effectiveness 1, but one small RCT (n=29) showed improvement over placebo that was not statistically significant 1
Alternative Options
Podophyllotoxin:
Autoinoculation:
- Clearance rate: 79.4% 2
- Novel approach for resistant cases
Treatments NOT Recommended
Imiquimod:
- Not shown to be of benefit compared with placebo in randomized controlled trials 1
- Despite theoretical immunomodulatory benefits, evidence does not support routine use
Special Populations
Immunocompromised Patients
- Develop severe and recalcitrant lesions 5
- May require cidofovir, imiquimod, or interferon 5
- Higher risk of diffuse MC with persistence and spread 6
- Active treatment strongly recommended over watchful waiting
Patients with Underlying Eczema
- Active treatment preferred over watchful waiting 1
- Lesions may be more symptomatic and prone to complications
Pregnant Patients
- Physical procedures (cryotherapy) are safe 5
- Avoid systemic or potentially teratogenic topical agents
Ocular Involvement (Conjunctivitis/Keratitis)
- Remove eyelid lesions to eliminate viral shedding 7, 8, 7
- Treatment options: incision and curettage (aggressive enough to cause bleeding), simple excision, excision and cautery, or cryotherapy 7, 8, 7
- Conjunctivitis may require weeks to resolve after lesion elimination 7, 8, 7
- Multiple lesions with minimal conjunctival inflammation in adults may indicate immunocompromised state 7, 8, 7
When to Treat vs. Watch
Treat actively when:
- Lesions are cosmetically bothersome
- Patient has underlying skin conditions (eczema)
- Risk of transmission is a concern (household contacts, athletes)
- Psychosocial burden (anxiety, embarrassment, isolation) 6
- Immunocompromised status
- Ocular involvement
Watchful waiting acceptable when:
- Minimal lesions in immunocompetent patient
- No cosmetic concerns
- No underlying skin conditions
- Patient/family preference after shared decision-making
Common Pitfalls
- Assuming all topical treatments are equally effective: Imiquimod specifically lacks RCT evidence despite widespread historical use
- Overlooking psychosocial impact: The "watch and wait" approach increases risk of spreading virus, extends infection duration, and causes anxiety/embarrassment 6
- Aggressive cryotherapy in darker skin: Risk of postinflammatory hyperpigmentation
- Missing immunocompromised state: Large, multiple lesions with minimal inflammation should prompt HIV or immunosuppression workup 7, 8, 7
- Treating ocular lesions inadequately: Must identify and treat nascent lesions to reduce recurrence risk 7, 8, 7
Return to Competition (Athletes)
For athletes with molluscum, specific return-to-competition guidelines exist from NCAA, NFHS, and NATA 1, though the evidence provided does not detail these specific criteria. Physical contact sports require particular attention to transmission prevention.